证券代码：600062 证券简称：华润双鹤 公告编号：临 2026－010 华润双鹤药业股份有限公司 关于公司部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 2026 年 2 月 9 日，华润双鹤药业股份有限公司(以下简称"公司") 及部分下属子公司参加了国家组织集采药品协议期满品种接续采购 办公室(以下简称"接续采购办公室")组织的集采药品协议期满品种 接续采购(以下简称"本次接续采购")。根据接续采购办公室于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中 选结果公示》，公司部分药品拟中选本次接续采购。现将相关情况公 告如下： | 拟中选企业 | 品种名称 | 药品适应症 | 规格 | | --- | --- | --- | --- | | 华润双鹤药业 股份有限公司 | 缬沙坦氢氯 噻嗪片 | 治疗单一药物不能充分控制血压的轻-中 | 每片含缬沙坦 80mg，氢氯噻 | | | | 度原发性高血压 | 嗪 12.5mg | ...

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for pharmaceutical products, with some of its drugs expected to be selected in the upcoming procurement results, which will be implemented by the end of March 2026 [1][2] Group 1: Company Performance - In the first three quarters of 2025, the sales revenue of Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of the total revenue [1] - The sales revenue of Nifedipine Controlled-Release Tablets was 138 million yuan, representing 1.67% of the total revenue [1] - The sales revenue of Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of the total revenue [1] - The sales revenue of Nifedipine Sustained-Release Tablets (II) was 108 million yuan, accounting for 1.30% of the total revenue [1] - The sales revenue of Irbesartan Dispersible Tablets was 79 million yuan, which is 0.95% of the total revenue [1] Group 2: Industry Context - The upcoming procurement process aims to maintain stable or decreasing prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces the risk of medication switching due to centralized procurement [2] - Although the selection may lead to a decrease in overall sales revenue, it is expected to solidify the company's existing market share, with potential for increased market penetration due to brand influence and reliable supply capabilities [2]

Core Viewpoint - China Resources Double Crane announced that the company and some subsidiaries participated in the national organized procurement for drugs whose agreements are expiring, with several drugs expected to be selected for procurement [1] Group 1: Selected Drugs and Revenue Impact - The main drugs expected to be selected include: - Valsartan and Hydrochlorothiazide Tablets with projected sales revenue of 517 million yuan, accounting for 4.61% of the 2024 annual revenue [1] - Nifedipine Controlled-Release Tablets with projected sales revenue of 147 million yuan, accounting for 1.31% of the 2024 annual revenue [1] - Enoxaparin Sodium Injection with projected sales revenue of 128 million yuan, accounting for 1.14% of the 2024 annual revenue [1] - Nifedipine Sustained-Release Tablets (II) with projected sales revenue of 118 million yuan, accounting for 1.05% of the 2024 annual revenue [1] - Irbesartan Dispersible Tablets with projected sales revenue of 110 million yuan, accounting for 0.98% of the 2024 annual revenue [1]

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in this procurement [1][2]. Group 1: Company Performance - In the first three quarters of 2025, the sales revenue for Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of total revenue [1]. - Sales revenue for Nifedipine Controlled Release Tablets was 138 million yuan, representing 1.67% of total revenue [1]. - Sales revenue for Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of total revenue [1]. - Sales revenue for Nifedipine Sustained Release Tablets (II) was 108 million yuan, which is 1.30% of total revenue [1]. - Sales revenue for Irbesartan Dispersible Tablets was 79 million yuan, accounting for 0.95% of total revenue [1]. Group 2: Industry Context - The procurement process is expected to stabilize or further reduce prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces risks associated with drug switching due to centralized procurement [2]. - Although the selection may lead to a decrease in overall sales amounts, it is anticipated to solidify existing market shares, with the company likely to enhance its market share due to its brand influence and reliable supply capabilities [2].

关键词 | DT新叶奖 |中科国生 | PEF新型全生物基功能纤维 生物基领域"奥斯卡"——「 2026(第4届)DT新叶奖 」已开启申报，将于第11届生物基大会 暨展览正式揭晓，并举行颁奖典礼。设置 四大奖项： 创新材料奖、创新应用奖、最具商业价 值奖、创新行业解决方案奖。 首轮报名截止 2月10日，享独家宣传。 参选单位&独家宣传 ： 万华化学 光华伟业 双枪科技 裕同包装 华润双鹤 利夫生物 中科国生 聚维元创 糖能科技 京博中聚 骐业科技 赛泓环境 河南浩森生物 军安绿色新材 华呋新材 麒 祥材料 泰安羽时 元一生物 华澄生物 世倍尔 播下环保 凤登绿能 和塑美 拜科瑞生物 碧嘉材 料 霍桐仪器 科幂仪器 无锡华辰 托摩根生物 谱键科技 碧普仪器 道生生物 德渊化工 漂莱特 碳和新材 微谱检测 武汉瑞鸣 树合科技 唯铂莱生物 合碳创物 深圳职业技术大学 百葵锐 ... 呋喃生物基材料全产业链先行者 —— 中科国生（杭 州） 科技有限公司 已确认参选 2026(第4届)DT新叶奖 ，以 PEF新型全生物基功能纤维 竞选 "创新应用 奖 " 。 中科国生是全球生物基材料制造领域的先行者，专注于呋喃类化学品 ...

Core Insights - The article highlights the fundraising activities of various investment funds in January 2026, with a total of 17 fundraising events amounting to over 270 billion RMB [2]. Fundraising Activities - Hengxu Capital completed the first closing of its fourth flagship fund, raising over 2 billion RMB, with a target final closing of 3.5 billion RMB [5][7]. - Dongfang Jiafu National SME Development Sub-Fund successfully completed its first closing of 1.6 billion RMB, with a total target of 2 billion RMB, focusing on advanced manufacturing, new materials, and health sectors [8][9]. - Zhangzhou Capital Operations Group and CICC established a healthcare fund with a total scale of 1 billion RMB, targeting traditional Chinese medicine and biomedicine [10][11]. - China Resources Capital launched a 1 billion RMB fund focused on chemical innovation drugs and high-end medical devices [12]. - Caitong Capital's two funds completed expansion, raising over 2.4 billion RMB to support the development of Taizhou Bay New Area [13]. - Kaibo Capital's Kaibo Nord Energy Storage Fund completed registration with a scale of 400 million RMB, focusing on independent energy storage projects [14][15]. - Deth Capital initiated a 500 million RMB fund aimed at the cultural and film sectors [18]. - The Baiyin Specialty Industry Fund, managed by Jincheng Capital, successfully registered with a scale of 200 million RMB, focusing on local specialty industries [19][20]. - Guangzhou Industrial Control Group launched a 1 billion RMB fund to support early-stage technology companies [21]. - Hushan Capital's new fund focusing on AI and semiconductor industries completed its first closing at 400 million RMB [22]. - Hubei Port and Shipping Development Fund completed expansion, reaching a scale of 2.8 billion RMB [24]. - Luxin Venture Capital initiated a 1 billion RMB fund targeting the artificial intelligence sector [26][27]. - Electric Science Investment established a 2 billion RMB electronic basic industry fund [28]. - Shangcheng Capital launched a 10 billion RMB fund to support AI and embodied intelligence industries [29]. - Beigong Investment and Jizhi Future established a 200 million RMB venture capital fund focusing on AI and new information technology [30]. - SPD Bank launched the "Puchuang Huazhang" science and technology direct investment fund with a scale of 500 million RMB [32][33]. - The "Golden Seed" fund for university student entrepreneurship was established with a scale of 45 million RMB [34][35].

证券代码：600062 证券简称：华润双鹤 公告编号：临2026－009 华润双鹤药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 同意公司为满足"十五五"战略发展需要，精准匹配患者临床需求，强化营销体系建设，推进营销资源整 合，组建营销管理中心。 11票同意，0票反对，0票弃权。 特此公告。 华润双鹤药业股份有限公司 公司第十届董事会第十七次会议的召开符合《公司法》和公司《章程》的有关规定。本次会议通知和材 料于2026年2月2日以邮件方式向全体董事发出，会议于2026年2月5日以通讯方式召开。出席会议的董事 应到11名，亲自出席会议的董事11名。 二、董事会会议审议情况 1、关于2026年境外佣金预算的议案 11票同意，0票反对，0票弃权。 2、关于组建营销管理中心的议案 一、董事会会议召开情况 董 事 会 2026年2月6日 ...

关键词| DT新叶奖 生物基领域"奥斯卡"——「 2026(第4届)DT新叶奖 」火热申报中，将于第11届生物基大会 正式揭晓获奖名单，并举行颁奖典礼。 首轮报名截止： 2月10日，享独家宣传 。 参选单位&独家宣传 ： 万华化学 光华伟业 双枪科技 裕同包装 华润双鹤 利夫生物 中科国生 聚维元创 糖能科技 京博中聚 骐业科技 瑞恒茂 河南浩森生物 军安绿色新材 华呋新材 麒祥 材料 泰安羽时 元一生物 华澄生物 播下环保 凤登绿能 和塑美 拜科瑞生物 壹科麦 碧嘉材料 科幂仪器 无锡华辰 托摩根生物 谱键科技 碧普仪器 道生生物 德渊化工 漂莱特 碳和新材 微 谱检测 武汉瑞鸣 树合科技 唯铂莱生物 ... ... 生物基创新应用场景有哪些？什么样的生物基应用解决方案值得被关注？ 为进一步挖掘生物基领域的创新应 用产品，「 # 2026DT新叶奖 」已邀 请了 20余 位 来 自 运动鞋服、汽车及零部件、包装、家具家电 等领域 的专 家和高管 加入评委团 。 从品牌用户的角度，生物基材料产品在以上领域应用 需兼顾材料性能带来的更高附加值、应用适配度和替代可行性，产品的合成路径清洁低耗，并能进 一步为终端产 ...

参选单位&独家宣传 ： 万华化学 光华伟业 双枪科技 裕同包装 华润双鹤 利夫生物 中科国生 聚维元创 糖能科技 京博中聚 骐业科技 瑞恒茂 河南浩森生物 军安绿色新材 华呋新材 麒祥 材料 泰安羽时 元一生物 华澄生物 播下环保 凤登绿能 和塑美 拜科瑞生物 壹科麦 碧嘉材料 科幂仪器 无锡华辰 托摩根生物 谱键科技 碧普仪器 道生生物 德渊化工 漂莱特 碳和新材 微 谱检测 武汉瑞鸣 树合科技 唯铂莱生物 ... ... 关键词| DT新叶奖 生物基领域"奥斯卡"——「 2026(第4届)DT新叶奖 」火热申报中，将于第11届生物基大会 正式揭晓获奖名单，并举行颁奖典礼。 首轮报名截止： 2月10日，享独家宣传 。 生物基创新应用场景有哪些？什么样的生物基应用解决方案值得被关注？ 为进一步挖掘生物基领域的创新应 用产品，「 # 2026DT新叶奖 」已邀 请了 20余 位 来 自 运动鞋服、汽车及零部件、包装、家具家电 等领域 的专 家和高管 加入评委团 。 从品牌用户的角度，生物基材料产品在以上领域应用 需兼顾材料性能带来的更高附加值、应用适配度和替代可行性，产品的合成路径清洁低耗，并能进 一步为终端产 ...

第十届董事会第十七次会议 2026 年 2 月 5 日 证券代码：600062 证券简称：华润双鹤 公告编号：临 2026－009 华润双鹤药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 1、关于2026年境外佣金预算的议案 11 票同意，0 票反对，0 票弃权。 2、关于组建营销管理中心的议案 同意公司为满足"十五五"战略发展需要，精准匹配患者临床需 求，强化营销体系建设，推进营销资源整合，组建营销管理中心。 11 票同意，0 票反对，0 票弃权。 特此公告。 华润双鹤药业股份有限公司 董 事 会 一、董事会会议召开情况 公司第十届董事会第十七次会议的召开符合《公司法》和公司《章 程》的有关规定。本次会议通知和材料于 2026 年 2 月 2 日以邮件方 式向全体董事发出，会议于 2026 年 2 月 5 日以通讯方式召开。出席 会议的董事应到 11 名，亲自出席会议的董事 11 名。 二、董事会会议审议情况 2026 年 2 月 6 日 ...